The symptom interval in children and adolescents with soft tissue sarcomas

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

BACKGROUND: In a series of 575 patients ≤21 years of age with soft tissue sarcomas (STSs), the authors investigated the association patterns between symptom interval (ie, the period between the onset of the first symptoms or signs of the disease and its definitive diagnosis) and patient/tumor characteristics or disease outcome (in terms of survival). METHODS: The analysis was based on multivariate models (linear for associations with patient/tumor characteristics and Cox's for survival). RESULTS: The symptom interval ranged between 1 week and 60 months (median, 2 months) and tended to be longer the older the patient (ie, the interval was longer in adolescents than in children) and the larger the tumor's size, and for tumors located at the extremities and for nonrhabdomyosarcoma STSs (as opposed to rhabdomyosarcomas). A longer symptom interval unfavorably influenced survival (P = .002), which was also significantly affected by the patient's age and the size and surgical stage of the tumor. A different pattern of association between symptom interval and survival emerged for different types of STS histology. CONCLUSIONS: Our study points to an independent prognostic effect of symptom interval that cannot be explained by its associations with other factors, such as patient's age or the site, size, stage, and histology of the tumor. Future studies should focus more on the possible causes of symptom interval in pediatric STS populations to enable corrective measures to be implemented to reduce the diagnostic delay.

Original languageEnglish
Pages (from-to)177-183
Number of pages7
JournalCancer
Volume116
Issue number1
DOIs
Publication statusPublished - Jan 1 2010

Fingerprint

Sarcoma
Neoplasms
Survival
Histology
Rhabdomyosarcoma
Signs and Symptoms
Linear Models
Extremities
Pediatrics
Population

Keywords

  • Delay
  • Pediatric cancer
  • Prognostic factors
  • Rhabdomyosarcoma
  • Soft tissue sarcoma
  • Survival
  • Symptom interval

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

@article{c8dde871f00441099caaea3546a7ab54,
title = "The symptom interval in children and adolescents with soft tissue sarcomas",
abstract = "BACKGROUND: In a series of 575 patients ≤21 years of age with soft tissue sarcomas (STSs), the authors investigated the association patterns between symptom interval (ie, the period between the onset of the first symptoms or signs of the disease and its definitive diagnosis) and patient/tumor characteristics or disease outcome (in terms of survival). METHODS: The analysis was based on multivariate models (linear for associations with patient/tumor characteristics and Cox's for survival). RESULTS: The symptom interval ranged between 1 week and 60 months (median, 2 months) and tended to be longer the older the patient (ie, the interval was longer in adolescents than in children) and the larger the tumor's size, and for tumors located at the extremities and for nonrhabdomyosarcoma STSs (as opposed to rhabdomyosarcomas). A longer symptom interval unfavorably influenced survival (P = .002), which was also significantly affected by the patient's age and the size and surgical stage of the tumor. A different pattern of association between symptom interval and survival emerged for different types of STS histology. CONCLUSIONS: Our study points to an independent prognostic effect of symptom interval that cannot be explained by its associations with other factors, such as patient's age or the site, size, stage, and histology of the tumor. Future studies should focus more on the possible causes of symptom interval in pediatric STS populations to enable corrective measures to be implemented to reduce the diagnostic delay.",
keywords = "Delay, Pediatric cancer, Prognostic factors, Rhabdomyosarcoma, Soft tissue sarcoma, Survival, Symptom interval",
author = "Andrea Ferrari and Rosalba Miceli and Michela Casanova and Cristina Meazza and Francesca Favini and Roberto Luksch and Serena Catania and Marco Fiore and Carlo Morosi and Luigi Mariani",
year = "2010",
month = "1",
day = "1",
doi = "10.1002/cncr.24695",
language = "English",
volume = "116",
pages = "177--183",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "1",

}

TY - JOUR

T1 - The symptom interval in children and adolescents with soft tissue sarcomas

AU - Ferrari, Andrea

AU - Miceli, Rosalba

AU - Casanova, Michela

AU - Meazza, Cristina

AU - Favini, Francesca

AU - Luksch, Roberto

AU - Catania, Serena

AU - Fiore, Marco

AU - Morosi, Carlo

AU - Mariani, Luigi

PY - 2010/1/1

Y1 - 2010/1/1

N2 - BACKGROUND: In a series of 575 patients ≤21 years of age with soft tissue sarcomas (STSs), the authors investigated the association patterns between symptom interval (ie, the period between the onset of the first symptoms or signs of the disease and its definitive diagnosis) and patient/tumor characteristics or disease outcome (in terms of survival). METHODS: The analysis was based on multivariate models (linear for associations with patient/tumor characteristics and Cox's for survival). RESULTS: The symptom interval ranged between 1 week and 60 months (median, 2 months) and tended to be longer the older the patient (ie, the interval was longer in adolescents than in children) and the larger the tumor's size, and for tumors located at the extremities and for nonrhabdomyosarcoma STSs (as opposed to rhabdomyosarcomas). A longer symptom interval unfavorably influenced survival (P = .002), which was also significantly affected by the patient's age and the size and surgical stage of the tumor. A different pattern of association between symptom interval and survival emerged for different types of STS histology. CONCLUSIONS: Our study points to an independent prognostic effect of symptom interval that cannot be explained by its associations with other factors, such as patient's age or the site, size, stage, and histology of the tumor. Future studies should focus more on the possible causes of symptom interval in pediatric STS populations to enable corrective measures to be implemented to reduce the diagnostic delay.

AB - BACKGROUND: In a series of 575 patients ≤21 years of age with soft tissue sarcomas (STSs), the authors investigated the association patterns between symptom interval (ie, the period between the onset of the first symptoms or signs of the disease and its definitive diagnosis) and patient/tumor characteristics or disease outcome (in terms of survival). METHODS: The analysis was based on multivariate models (linear for associations with patient/tumor characteristics and Cox's for survival). RESULTS: The symptom interval ranged between 1 week and 60 months (median, 2 months) and tended to be longer the older the patient (ie, the interval was longer in adolescents than in children) and the larger the tumor's size, and for tumors located at the extremities and for nonrhabdomyosarcoma STSs (as opposed to rhabdomyosarcomas). A longer symptom interval unfavorably influenced survival (P = .002), which was also significantly affected by the patient's age and the size and surgical stage of the tumor. A different pattern of association between symptom interval and survival emerged for different types of STS histology. CONCLUSIONS: Our study points to an independent prognostic effect of symptom interval that cannot be explained by its associations with other factors, such as patient's age or the site, size, stage, and histology of the tumor. Future studies should focus more on the possible causes of symptom interval in pediatric STS populations to enable corrective measures to be implemented to reduce the diagnostic delay.

KW - Delay

KW - Pediatric cancer

KW - Prognostic factors

KW - Rhabdomyosarcoma

KW - Soft tissue sarcoma

KW - Survival

KW - Symptom interval

UR - http://www.scopus.com/inward/record.url?scp=74549169855&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=74549169855&partnerID=8YFLogxK

U2 - 10.1002/cncr.24695

DO - 10.1002/cncr.24695

M3 - Article

VL - 116

SP - 177

EP - 183

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 1

ER -